A study comparing the effectiveness of oral versus intravenous ketamine for patients with suicidal thoughts.

Phase 2

• Registration Number: CTRI/2024/01/061125
• Lead Sponsor: A

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 January 2024

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Subjects aged 18 to 65 years with suicidal ideation having HAMD score more than or equal to 14 and Beck

suicidal ideation scale of more than or equal to 5

2. Subjects willing to take Ketamine after informed written consent.

Exclusion Criteria

1. Contraindication to the administration of ketamine, especially present diagnosis or

antecedents of clinically relevant cardiovascular disorders such as stroke, heart attack,

etc.

2. If they had any, those with present or past diagnosis of glaucoma, intracranial

hypertension.

3. Current diagnosis of schizophrenia or other psychotic disorder (including psychotic

disorder due to general medical condition, substance-induced psychotic disorder, or

mania) as defined in the ICD-11

4. Patients with any known hypersensitivity to ketamine.

5. Subjects having any substance dependence, intoxication or withdrawal within 1

month period

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Examining decline in Beck scale for suicide ideation score in patients after intervention. <br/ ><br>Timepoint: 2 hours, Day 1, Day 3, Day 7 after intervention.

Secondary Outcome Measures

Name	Time	Method
Examining the decline in the HAM-D score in patients after intervention.Timepoint: 2 hours, Day 1, Day 3, Day 7 after intervention.